🏥 Health
7h ago
First Clinical Trial in MOGAD Meets Primary Endpoint
Source ↗
👁 0
💬 0
(MedPage Today) -- The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Satralizumab reduced the risk of...
Satralizumab reduced the risk of...
Comments (0)